Large-scale testing (Phase 3)UnknownNCT00532727What this trial is testingTriple Negative Breast Cancer TrialWho this might be right forBreast Cancer Institute of Cancer Research, United Kingdom 400
Testing effectiveness (Phase 2)UnknownNCT03906669What this trial is testingA Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.Who this might be right forEarly-stage Breast CancerHormone Receptor Positive Tumor St Vincent's Hospital 200
Large-scale testing (Phase 3)UnknownNCT01622361What this trial is testingPremenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast CancerWho this might be right forBreast Cancer Asan Medical Center 290
Testing effectiveness (Phase 2)Study completedNCT02988986What this trial is testingTAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast CancerWho this might be right forEstrogen Receptor Positive Breast Cancer The Methodist Hospital Research Institute 28
Large-scale testing (Phase 3)Looking for participantsNCT07541079What this trial is testingA Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)Who this might be right forEarly Breast Cancer Genentech, Inc. 300
Testing effectiveness (Phase 2)Ended earlyNCT00133796What this trial is testingNeoadjuvant Herceptin in Patients With Breast CancerWho this might be right forBREAST CANCER Mothaffar Rimawi 40
Not applicableActive Not RecruitingNCT05529862What this trial is testingTrans-RosaLEE Study: a Biomarker-directed, Translational StudyWho this might be right forAdvanced or Metastatic Breast Cancer (BC) Institut Paoli-Calmettes 115
Testing effectiveness (Phase 2)Ended earlyNCT01498588What this trial is testingTrial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast CancerWho this might be right forBreast NeoplasmsBreast CancerBreast Tumors+3 more Emory University 7
Not applicableLooking for participantsNCT06930859What this trial is testingNon-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in RussiaWho this might be right forBreast Cancer Novartis Pharmaceuticals 2,766
Large-scale testing (Phase 3)Looking for participantsNCT07022483What this trial is testingStudy of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial CancerWho this might be right forEndometrial Cancer Daiichi Sankyo 710
Early research (Phase 1)Study completedNCT02063724What this trial is testingHER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast CancerWho this might be right forBreast Cancer H. Lee Moffitt Cancer Center and Research Institute 15
Testing effectiveness (Phase 2)Study completedNCT00615940What this trial is testingCombination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Heidelberg Pharma AG 132
Early research (Phase 1)Study completedNCT01471847What this trial is testingA Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to TrastuzumabWho this might be right forLocally Advance Breast Cancer (LABC)Metastatic Breast Cancer (MBC) Novartis Pharmaceuticals 5
Testing effectiveness (Phase 2)Looking for participantsNCT05816655What this trial is testingComparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Korea University Guro Hospital 202
Large-scale testing (Phase 3)Study completedNCT05629949What this trial is testingA Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast CancerWho this might be right forBreast Cancer Qilu Pharmaceutical Co., Ltd. 474
Testing effectiveness (Phase 2)Study completedNCT00777049What this trial is testingStudy of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast CancerWho this might be right forBreast Cancer Translational Research in Oncology 54
Testing effectiveness (Phase 2)Study completedNCT00331552What this trial is testingDoxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast CancerWho this might be right forHER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more University of Washington 30
Large-scale testing (Phase 3)Study completedNCT04799249What this trial is testingTrilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)Who this might be right forTNBC - Triple-Negative Breast CancerBreast Cancer G1 Therapeutics, Inc. 194
Testing effectiveness (Phase 2)Active Not RecruitingNCT05480384What this trial is testingAdjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal JunctionWho this might be right forEsophageal AdenocarcinomaEsophageal CancerHER-2 Protein Overexpression+1 more Brown University 1
Not applicableStudy completedNCT04181333What this trial is testingSafety and Efficacy of Trastuzumab BSWho this might be right forGastric Cancer Pfizer 8